Senti Biosciences Holdings, Inc. SEC filings SNTI
Senti Biosciences Holdings, Inc. has 367 filings in SEC EDGAR's recent list, going back to Apr 2, 2021. Its latest annual report, Form ARS, was filed on Jul 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 27, 2026 (officer or director change, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Other events
|
Oct 27, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, Acquisition or sale of assets, Unregistered share sale
|
Oct 26, 2026 | Oct 21, 2026 |
| 4 | Insider transaction | Oct 23, 2026 | Oct 21, 2026 |
| 4 | Insider transaction | Oct 23, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 15, 2026 | Oct 15, 2026 |
| DEFA14A | Additional proxy material | Oct 13, 2026 | — |
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 8, 2026 |
| EFFECT | Filing | Sep 24, 2026 | — |
| DEFM14A | Filing | Sep 24, 2026 | — |
| 424B3 | Prospectus | Sep 24, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Sep 24, 2026 | Sep 23, 2026 |
| PRER14A | Filing | Sep 24, 2026 | — |
| S-3/A | Filing | Sep 22, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Sep 11, 2026 | — |
| S-3/A | Filing | Sep 10, 2026 | — |
| PRER14A | Filing | Sep 4, 2026 | — |
| DEFA14A | Additional proxy material | Sep 4, 2026 | — |
| 8-K |
Current report
Material agreement, New debt
|
Sep 4, 2026 | Sep 3, 2026 |
| DEFA14A | Additional proxy material | Sep 2, 2026 | — |
| 8-K |
Current report
Material agreement, Listing notice
|
Sep 2, 2026 | Aug 27, 2026 |
| DEFA14A | Additional proxy material | Aug 20, 2026 | — |
| 8-K |
Current report
Material agreement, New debt
|
Aug 20, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| ARS | Annual report to shareholders | Jul 21, 2026 | Dec 31, 2025 |
| PREM14A | Filing | Jul 21, 2026 | Aug 18, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jul 16, 2026 | — |
| S-3/A | Filing | Jul 16, 2026 | — |
| DEFA14A | Additional proxy material | Jul 15, 2026 | — |
| 8-K |
Current report
Material agreement, Results of operations, Change in control, Regulation FD disclosure, Other events
|
Jul 15, 2026 | Jul 14, 2026 |
| S-3 | Shelf registration | Jun 18, 2026 | — |
| D | Filing | Jun 4, 2026 | — |
| 8-K |
Current report
Material agreement, New debt
|
May 26, 2026 | May 20, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
May 14, 2026 | May 14, 2026 |
| 15-12G | Deregistration | May 8, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | May 4, 2026 | — |
| 424B5 | Prospectus supplement | May 1, 2026 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Change in control
|
May 1, 2026 | Apr 27, 2026 |
| EFFECT | Filing | Apr 29, 2026 | — |
| EFFECT | Filing | Apr 29, 2026 | — |
| EFFECT | Filing | Apr 29, 2026 | — |
| EFFECT | Filing | Apr 29, 2026 | — |
| 10-K/A | Amended annual report | Apr 29, 2026 | Dec 31, 2025 |
| S-8 | Employee stock plan registration | Apr 24, 2026 | — |
| S-8 POS | Filing | Apr 24, 2026 | — |
| S-8 POS | Filing | Apr 24, 2026 | — |
| S-8 POS | Filing | Apr 24, 2026 | — |
| S-8 POS | Filing | Apr 24, 2026 | — |
| POS AM | Filing | Apr 24, 2026 | — |
| POS AM | Filing | Apr 24, 2026 | — |
| POS AM | Filing | Apr 24, 2026 | — |
| 8-K12B | Filing | Apr 24, 2026 | Apr 24, 2026 |
| POS AM | Filing | Apr 24, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 16, 2026 | — |
| 8-K |
Current report
Other events
|
Apr 1, 2026 | Apr 1, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 31, 2026 | — |
| 10-K | Annual report | Mar 27, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 27, 2026 | Mar 27, 2026 |
| 8-K |
Current report
Material agreement
|
Mar 19, 2026 | Mar 17, 2026 |
| 4 | Insider transaction | Mar 11, 2026 | Mar 9, 2026 |
| 4 | Insider transaction | Mar 11, 2026 | Mar 9, 2026 |
| 4 | Insider transaction | Feb 3, 2026 | Feb 2, 2026 |
| 4 | Insider transaction | Feb 3, 2026 | Feb 2, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 20, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 9, 2025 | Dec 9, 2025 |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2025 | Nov 13, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Sep 2, 2025 | — |
| 10-Q | Quarterly report | Aug 7, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 4 | Insider transaction | Jul 21, 2025 | Jul 18, 2025 |
| 3 | Initial insider ownership | Jul 21, 2025 | Jul 18, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 18, 2025 | Jul 18, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 30, 2025 | Jun 25, 2025 |
| 4 | Insider transaction | Jun 27, 2025 | Jun 25, 2025 |
| 4 | Insider transaction | Jun 27, 2025 | Jun 25, 2025 |
| 4 | Insider transaction | Jun 27, 2025 | Jun 25, 2025 |
| 4 | Insider transaction | Jun 27, 2025 | Jun 25, 2025 |
| 4 | Insider transaction | Jun 27, 2025 | Jun 25, 2025 |
| 4 | Insider transaction | Jun 27, 2025 | Jun 25, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 18, 2025 | Jun 18, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 7, 2025 | — |
| 10-Q | Quarterly report | May 6, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 6, 2025 | May 6, 2025 |
| ARS | Annual report to shareholders | Apr 30, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 30, 2025 | — |
| DEF 14A | Proxy statement | Apr 30, 2025 | Jun 25, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Apr 28, 2025 | Apr 28, 2025 |
| EFFECT | Filing | Mar 31, 2025 | — |
| EFFECT | Filing | Mar 31, 2025 | — |
| 424B5 | Prospectus supplement | Mar 31, 2025 | — |
| CORRESP | Letter to the SEC | Mar 27, 2025 | — |
| CORRESP | Letter to the SEC | Mar 27, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 26, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 26, 2025 | — |
| 8-K |
Current report
Material agreement
|
Mar 24, 2025 | Mar 20, 2025 |
| S-3 | Shelf registration | Mar 21, 2025 | — |
| S-3 | Shelf registration | Mar 21, 2025 | — |
| 10-K | Annual report | Mar 20, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 20, 2025 | Mar 20, 2025 |
| SCHEDULE 13D | Ownership over 5% (active) | Mar 17, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 17, 2025 | — |
| 4 | Insider transaction | Mar 14, 2025 | Mar 10, 2025 |
| 3 | Initial insider ownership | Mar 13, 2025 | Mar 6, 2025 |
| SCHEDULE 13D | Ownership over 5% (active) | Mar 13, 2025 | — |
| 4 | Insider transaction | Mar 12, 2025 | Mar 10, 2025 |
| 3 | Initial insider ownership | Mar 12, 2025 | Mar 6, 2025 |
| 4 | Insider transaction | Mar 12, 2025 | Mar 10, 2025 |
| 4 | Insider transaction | Mar 11, 2025 | Mar 7, 2025 |
| 4 | Insider transaction | Mar 11, 2025 | Mar 10, 2025 |
| 4 | Insider transaction | Mar 11, 2025 | Mar 7, 2025 |
| 4 | Insider transaction | Mar 11, 2025 | Mar 7, 2025 |
| 4 | Insider transaction | Mar 11, 2025 | Mar 7, 2025 |
| 4 | Insider transaction | Mar 11, 2025 | Mar 7, 2025 |
| 4 | Insider transaction | Mar 11, 2025 | Mar 7, 2025 |
| 3 | Initial insider ownership | Mar 11, 2025 | Mar 7, 2025 |
| 4 | Insider transaction | Mar 11, 2025 | Mar 7, 2025 |
| 3 | Initial insider ownership | Mar 11, 2025 | Mar 3, 2025 |
| 4 | Insider transaction | Mar 10, 2025 | Mar 6, 2025 |
| 4 | Insider transaction | Mar 10, 2025 | Mar 6, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 10, 2025 | — |
| 8-K |
Current report
Officer or director change, Other events
|
Mar 10, 2025 | Mar 6, 2025 |
| S-8 | Employee stock plan registration | Mar 7, 2025 | — |
| 8-K |
Current report
Shareholder vote results
|
Mar 7, 2025 | Mar 6, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Feb 25, 2025 | Feb 23, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 14, 2025 | — |
| 4 | Insider transaction | Feb 6, 2025 | Feb 4, 2025 |
| 4 | Insider transaction | Feb 6, 2025 | Feb 4, 2025 |
| 8-K |
Current report
Officer or director change
|
Feb 6, 2025 | Jan 31, 2025 |
| DEF 14A | Proxy statement | Jan 27, 2025 | Mar 6, 2025 |
| PRE 14A | Preliminary proxy statement | Jan 15, 2025 | Mar 6, 2025 |
| 8-K |
Current report
New debt, Unregistered share sale, Other events
|
Jan 6, 2025 | Dec 31, 2024 |
| D | Filing | Dec 19, 2024 | — |
| 8-K |
Current report
Other events
|
Dec 16, 2024 | Dec 16, 2024 |
| 4 | Insider transaction | Dec 11, 2024 | Dec 9, 2024 |
| 4 | Insider transaction | Dec 10, 2024 | Dec 9, 2024 |
| 3 | Initial insider ownership | Dec 10, 2024 | Dec 9, 2024 |
| 4 | Insider transaction | Dec 10, 2024 | Dec 9, 2024 |
| 3 | Initial insider ownership | Dec 10, 2024 | Dec 9, 2024 |
| 4 | Insider transaction | Dec 10, 2024 | Dec 9, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Dec 4, 2024 | — |
| 8-K |
Current report
Other events
|
Dec 3, 2024 | Dec 3, 2024 |
| 144 | Notice of proposed sale | Dec 2, 2024 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Change to shareholder rights, Officer or director change, Bylaw or fiscal year change, Other events
|
Dec 2, 2024 | Nov 25, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 2, 2024 | Dec 2, 2024 |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2024 | Nov 14, 2024 |
| 8-K |
Current report
Listing notice
|
Oct 25, 2024 | Oct 22, 2024 |
| 8-K |
Current report
Material agreement
|
Sep 27, 2024 | Sep 23, 2024 |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 13, 2024 | Aug 13, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jul 17, 2024 | Jul 17, 2024 |
| 8-K |
Current report
Material agreement
|
Jul 16, 2024 | Jul 16, 2024 |
| 4 | Insider transaction | Jul 12, 2024 | Jul 10, 2024 |
| 4 | Insider transaction | Jul 12, 2024 | Jul 10, 2024 |
| 4 | Insider transaction | Jul 12, 2024 | Jul 10, 2024 |
| 4 | Insider transaction | Jul 12, 2024 | Jul 10, 2024 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Shareholder vote results
|
Jul 12, 2024 | Jul 10, 2024 |
| ARS | Annual report to shareholders | May 29, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | May 29, 2024 | — |
| DEF 14A | Proxy statement | May 29, 2024 | Jul 10, 2024 |
| PRE 14A | Preliminary proxy statement | May 17, 2024 | May 17, 2024 |
| 8-K |
Current report
Officer or director change
|
May 17, 2024 | May 14, 2024 |
| 3 | Initial insider ownership | May 9, 2024 | May 4, 2024 |
| 10-Q | Quarterly report | May 9, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 9, 2024 | May 9, 2024 |
| 8-K |
Current report
Officer or director change
|
May 2, 2024 | Apr 26, 2024 |
| 10-K/A | Amended annual report | Apr 26, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Officer or director change
|
Apr 26, 2024 | Apr 23, 2024 |
| 10-K | Annual report | Mar 21, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 21, 2024 | Mar 21, 2024 |
| 8-K |
Current report
Listing notice
|
Feb 6, 2024 | Feb 6, 2024 |
| 4 | Insider transaction | Feb 2, 2024 | Feb 1, 2024 |
| 4 | Insider transaction | Feb 2, 2024 | Feb 1, 2024 |
| 4 | Insider transaction | Feb 2, 2024 | Feb 1, 2024 |
| S-8 | Employee stock plan registration | Jan 10, 2024 | — |
| 8-K |
Current report
Exit or restructuring costs, Other events
|
Jan 5, 2024 | Jan 3, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 22, 2023 | Dec 22, 2023 |
| 10-Q | Quarterly report | Nov 14, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2023 | Nov 13, 2023 |
| 424B3 | Prospectus | Nov 13, 2023 | — |
| 424B3 | Prospectus | Nov 13, 2023 | — |
| 8-K |
Current report
Material agreement
|
Nov 6, 2023 | Nov 6, 2023 |
| EFFECT | Filing | Nov 3, 2023 | — |
| EFFECT | Filing | Nov 3, 2023 | — |
| POS AM | Filing | Nov 1, 2023 | — |
| POS AM | Filing | Nov 1, 2023 | — |
| 424B3 | Prospectus | Aug 11, 2023 | — |
| 424B3 | Prospectus | Aug 11, 2023 | — |
| 424B3 | Prospectus | Aug 11, 2023 | — |
| 424B3 | Prospectus | Aug 11, 2023 | — |
| 10-Q | Quarterly report | Aug 11, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2023 | Aug 11, 2023 |
| 8-K |
Current report
Listing notice
|
Aug 11, 2023 | Aug 7, 2023 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SNTI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1854270
- Former names
- Senti Biosciences, Inc. (until May 8, 2026); Senti Biosciences, Inc.\ (until Jun 28, 2022); Dynamics Special Purpose Corp. (until Jun 13, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.